Cogent Biosciences (COGT) Cash from Financing Activities: 2017-2021
Historic Cash from Financing Activities for Cogent Biosciences (COGT) over the last 3 years, with Dec 2021 value amounting to $38.0 million.
- Cogent Biosciences' Cash from Financing Activities fell 68.88% to $38.0 million in Q4 2021 from the same period last year, while for Dec 2021 it was $160.1 million, marking a year-over-year decrease of 31.04%. This contributed to the annual value of $214.5 million for FY2024, which is 31.13% up from last year.
- Per Cogent Biosciences' latest filing, its Cash from Financing Activities stood at $38.0 million for Q4 2021, which was up 69,001.82% from $55,000 recorded in Q3 2021.
- In the past 5 years, Cogent Biosciences' Cash from Financing Activities registered a high of $122.1 million during Q4 2020, and its lowest value of -$734,000 during Q4 2017.
- Over the past 3 years, Cogent Biosciences' median Cash from Financing Activities value was $73,000 (recorded in 2020), while the average stood at $30.0 million.
- As far as peak fluctuations go, Cogent Biosciences' Cash from Financing Activities spiked by 563.64% in 2020, and later tumbled by 216.44% in 2021.
- Cogent Biosciences' Cash from Financing Activities (Quarterly) stood at -$734,000 in 2017, then skyrocketed by 153.81% to $395,000 in 2018, then tumbled by 99.86% to $97,000 in 2019, then plummeted by 36.08% to $122.1 million in 2020, then crashed by 68.88% to $38.0 million in 2021.
- Its last three reported values are $38.0 million in Q4 2021, $55,000 for Q3 2021, and -$85,000 during Q1 2021.